CATO SMS has announced that it has acquired Array Biostatistics to expand its offering of specialized clinical research solutions. The company plans to invest in growing Array and its biostatistical capabilities.

Both Array and CATO SMS offer highly specialized services that aim to expedite and support drug development for small and emerging biopharmaceutical companies. By acquiring Array, CATO SMS adds expertise and scale to its full-service biostatistical consulting, analysis and programming capabilities. CATO SMS will focus on growing these capabilities and its team of senior biostaticians and statistical programmers, as it continues to expand its product development consulting and clinical trial operations. Sandy Ferber, chief executive officer of Array, will continue to lead Array and will spearhead CATO SMS’ overall biometrics offering.

“We are thrilled to have this opportunity to grow our biostatistical offering in partnership with CATO SMS. Together, we share core values centered around high quality and a commitment to providing our clients with expert and highly personalized service,” said Ms. Ferber.

Mark A. Goldberg, MD, executive chairman, CATO SMS, added, “We are excited to welcome Array’s impressive team to CATO SMS. The Array acquisition furthers our goal of providing our clients with a comprehensive portfolio of specialized solutions to best support development in complex therapeutic areas including oncology, rare and orphan indications, and cell and gene therapy, among others.”

For more information, read the full release, 